loading page

Repositioning an old antihelminthic agent of niclosamide in human disease and cancer
  • +3
  • Guiling Wang,
  • Jinxiu Du,
  • Zhan Wang,
  • Junyi Ren,
  • Huan Wang,
  • Jia Liu
Guiling Wang
China Medical University

Corresponding Author:[email protected]

Author Profile
Jinxiu Du
China Medical University
Author Profile
Zhan Wang
China Medical University
Author Profile
Junyi Ren
China Medical University
Author Profile
Huan Wang
China Medical University
Author Profile
Jia Liu
China Medical University
Author Profile

Abstract

Niclosamide is a FDA-approved anthelminthic drug for the treatment of parasitic infection. However, over the past few years, the increasing evidence has shown that Niclosamide could treat diseases beyond parasitic diseases, which include metabolic diseases, immune system diseases, bacterial and viral infections, other types of diseases and cancer. Therefore, we systematically review the pharmaceutical activities and therapeutic prospects of Niclosamide in human disease and cancer, and summarize the related molecular mechanisms and signaling pathways, which provides theoretical support for the new therapeutic value of old drug.